Criteria for initiating and continuing DHM vary widely among U.S. level 3 and level 4 NICUs. Donor human milk use is more frequent in NICUs with many very low-birth-weight admissions and among Vermont-Oxford Network participants. Further research is needed to define short- and long-term outcomes and cost benefits of DHM use in subgroups of NICU patients, particularly for uses other than necrotizing enterocolitis prevention.
No takes yet. Share an insight, caveat, or question.
Hagadorn et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: